Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions

This article reviews strategies for the initiation of basal insulin therapy, with an emphasis on the characteristics and titration of second-generation basal insulins, introducing current guidelines and offering suggestions for recognizing and overcoming barriers to insulin therapy in the management of T2D.
Source: Journal of the American Board of Family Medicine - Category: Primary Care Authors: Tags: Clinical Review Source Type: research

Related Links:

ConclusionsFor patients with Type 2 diabetes, team-based care improves blood glucose, blood pressure, and lipid levels.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Publication date: July 2019Source: American Journal of Preventive Medicine, Volume 57, Issue 1Author(s): Community Preventive Services Task Force
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
This study aims to investigate the antidiabetic effects of the hot water extract of C. nitida seeds in type 2 diabetic rats.MethodsType 2 diabetic rats were orally administered with low (150 mg/kg bw) and high (300 mg/kg bw) doses of the hot water extract for 6 wk and thereafter, blood glucose, insulin level, lipid profile, pancreatic β-cell function, perfusion and morphology, redox imbalance, glycolytic and cholinergic enzymes, as well as of caspase-3 and Nrf2 expressions were measured.ResultsTreatment with the extract led to significant depleted levels of blood glucose, triglycerides, LDL-c, fructosamine, ALT,...
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
[12-16-2015] The U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
[9-10-2015] The U.S. Food and Drug Administration (FDA) has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures and added new information about decreased bone mineral density.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Guidelines address CGM goals for type 1 and type 2 diabetes, older/high-risk patients, and pregnant women with diabetes.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Publication date: Available online 17 June 2019Source: Genes &DiseasesAuthor(s): Fateme Sadat Eshaghi, Hamideh Ghazizadeh, Sakine Kazami Nooreini, Ameneh Timar, Habibollah Esmaeily, Mehrane Mehramiz, Amir Avan, Majid Ghayour-MobarhanAbstractMetabolic syndrome (MetS) is a clustering of metabolic abnormalities that is associated with increased risk of developing cardiovascular disease and type 2 diabetes. There is growing body of data showing the associations of genetic variants of the genes involved in the PI3K/AKT/mTOR pathway with diabetes and obesity. We aimed to investigate the association between MetS and its compo...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
TUESDAY, June 18, 2019 -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced. Approved to treat type 2 diabetes in adults in 2010, Victoza is the...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide) Sponsor:   Novo Nordisk A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
TUESDAY, June 18, 2019 -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced yesterday. Approved to treat type 2 diabetes in adults in 2010,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Diabetes Type 2 | Education | Endocrinology | Insulin | Primary Care | Toxicology